Literature DB >> 34787357

Specific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties.

Zachary R Grese1, Alliny Cs Bastos1, Lohany D Mamede1, Rachel L French1, Timothy M Miller2, Yuna M Ayala1.   

Abstract

TDP-43 is an RNA-binding protein that forms ribonucleoprotein condensates via liquid-liquid phase separation (LLPS) and regulates gene expression through specific RNA interactions. Loss of TDP-43 protein homeostasis and dysfunction are tied to neurodegenerative disorders, mainly amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Alterations of TDP-43 LLPS properties may be linked to protein aggregation. However, the mechanisms regulating TDP-43 LLPS are ill-defined, particularly how TDP-43 association with specific RNA targets regulates TDP-43 condensation remains unclear. We show that RNA binding strongly promotes TDP-43 LLPS through sequence-specific interactions. RNA-driven condensation increases with the number of adjacent TDP-43-binding sites and is also mediated by multivalent interactions involving the amino and carboxy-terminal TDP-43 domains. The physiological relevance of RNA-driven TDP-43 condensation is supported by similar observations in mammalian cellular lysate. Importantly, we find that TDP-43-RNA association maintains liquid-like properties of the condensates, which are disrupted in the presence of ALS-linked TDP-43 mutations. Altogether, RNA binding plays a central role in modulating TDP-43 condensation while maintaining protein solubility, and defects in this RNA-mediated activity may underpin TDP-43-associated pathogenesis.
© 2021 The Authors.

Entities:  

Keywords:  RNA-binding protein; TDP-43; amyotrophic lateral sclerosis; liquid-liquid phase separation; ribonucleoprotein (RNP) granules

Mesh:

Substances:

Year:  2021        PMID: 34787357      PMCID: PMC8647020          DOI: 10.15252/embr.202153632

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  66 in total

1.  RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.

Authors:  Jacob R Mann; Amanda M Gleixner; Jocelyn C Mauna; Edward Gomes; Michael R DeChellis-Marks; Patrick G Needham; Katie E Copley; Bryan Hurtle; Bede Portz; Noah J Pyles; Lin Guo; Christopher B Calder; Zachary P Wills; Udai B Pandey; Julia K Kofler; Jeffrey L Brodsky; Amantha Thathiah; James Shorter; Christopher J Donnelly
Journal:  Neuron       Date:  2019-02-27       Impact factor: 17.173

2.  Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function.

Authors:  Wen Li; Ashley N Reeb; Binyan Lin; Praveen Subramanian; Erin E Fey; Catherine R Knoverek; Rachel L French; Eileen H Bigio; Yuna M Ayala
Journal:  J Biol Chem       Date:  2017-02-06       Impact factor: 5.157

3.  Specific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties.

Authors:  Zachary R Grese; Alliny Cs Bastos; Lohany D Mamede; Rachel L French; Timothy M Miller; Yuna M Ayala
Journal:  EMBO Rep       Date:  2021-11-17       Impact factor: 8.807

4.  Characterizing the RNA targets and position-dependent splicing regulation by TDP-43.

Authors:  James R Tollervey; Tomaž Curk; Boris Rogelj; Michael Briese; Matteo Cereda; Melis Kayikci; Julian König; Tibor Hortobágyi; Agnes L Nishimura; Vera Zupunski; Rickie Patani; Siddharthan Chandran; Gregor Rot; Blaž Zupan; Christopher E Shaw; Jernej Ule
Journal:  Nat Neurosci       Date:  2011-02-27       Impact factor: 24.884

5.  Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization.

Authors:  Amandine Molliex; Jamshid Temirov; Jihun Lee; Maura Coughlin; Anderson P Kanagaraj; Hong Joo Kim; Tanja Mittag; J Paul Taylor
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

6.  TDP-43 regulates site-specific 2'-O-methylation of U1 and U2 snRNAs via controlling the Cajal body localization of a subset of C/D scaRNAs.

Authors:  Keiichi Izumikawa; Yuko Nobe; Hideaki Ishikawa; Yoshio Yamauchi; Masato Taoka; Ko Sato; Hiroshi Nakayama; Richard J Simpson; Toshiaki Isobe; Nobuhiro Takahashi
Journal:  Nucleic Acids Res       Date:  2019-03-18       Impact factor: 16.971

7.  An Intramolecular Salt Bridge Linking TDP43 RNA Binding, Protein Stability, and TDP43-Dependent Neurodegeneration.

Authors:  Brittany N Flores; Xingli Li; Ahmed M Malik; Jose Martinez; Asim A Beg; Sami J Barmada
Journal:  Cell Rep       Date:  2019-04-23       Impact factor: 9.423

8.  The cooperative binding of TDP-43 to GU-rich RNA repeats antagonizes TDP-43 aggregation.

Authors:  Juan Carlos Rengifo-Gonzalez; Krystel El Hage; Marie-Jeanne Clément; Emilie Steiner; Vandana Joshi; Pierrick Craveur; Dominique Durand; David Pastré; Ahmed Bouhss
Journal:  Elife       Date:  2021-09-07       Impact factor: 8.140

9.  TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.

Authors:  Jemeen Sreedharan; Ian P Blair; Vineeta B Tripathi; Xun Hu; Caroline Vance; Boris Rogelj; Steven Ackerley; Jennifer C Durnall; Kelly L Williams; Emanuele Buratti; Francisco Baralle; Jacqueline de Belleroche; J Douglas Mitchell; P Nigel Leigh; Ammar Al-Chalabi; Christopher C Miller; Garth Nicholson; Christopher E Shaw
Journal:  Science       Date:  2008-02-28       Impact factor: 47.728

10.  Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.

Authors:  Ze'ev Melamed; Jone López-Erauskin; Michael W Baughn; Ouyang Zhang; Kevin Drenner; Ying Sun; Fernande Freyermuth; Moira A McMahon; Melinda S Beccari; Jon W Artates; Takuya Ohkubo; Maria Rodriguez; Nianwei Lin; Dongmei Wu; C Frank Bennett; Frank Rigo; Sandrine Da Cruz; John Ravits; Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Nat Neurosci       Date:  2019-01-14       Impact factor: 24.884

View more
  9 in total

1.  Specific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties.

Authors:  Zachary R Grese; Alliny Cs Bastos; Lohany D Mamede; Rachel L French; Timothy M Miller; Yuna M Ayala
Journal:  EMBO Rep       Date:  2021-11-17       Impact factor: 8.807

Review 2.  Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.

Authors:  Lindsey R Hayes; Petr Kalab
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 6.088

Review 3.  Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.

Authors:  Isabelle Landrieu; Elian Dupré; Davy Sinnaeve; Léa El Hajjar; Caroline Smet-Nocca
Journal:  Front Chem       Date:  2022-05-12       Impact factor: 5.545

4.  Sequence Determinants of TDP-43 Ribonucleoprotein Condensate Formation and Axonal Transport in Neurons.

Authors:  Sonali S Vishal; Denethi Wijegunawardana; Muthu Raj Salaikumaran; Pallavi P Gopal
Journal:  Front Cell Dev Biol       Date:  2022-05-12

Review 5.  Herpesvirus Replication Compartments: Dynamic Biomolecular Condensates?

Authors:  Enrico Caragliano; Wolfram Brune; Jens B Bosse
Journal:  Viruses       Date:  2022-05-04       Impact factor: 5.818

Review 6.  Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases.

Authors:  Jenny L Carey; Lin Guo
Journal:  Front Mol Biosci       Date:  2022-02-02

7.  TDP-43 Oligomerization and Phase Separation Properties Are Necessary for Autoregulation.

Authors:  Lydia C Koehler; Zachary R Grese; Alliny C S Bastos; Lohany D Mamede; Tomasz Heyduk; Yuna M Ayala
Journal:  Front Neurosci       Date:  2022-04-14       Impact factor: 4.677

8.  Recent trends in studies of biomolecular phase separation.

Authors:  Chan-Geun Kim; Da-Eun Hwang; Rajeev Kumar; Min Chung; Yu-Gon Eom; Hyunji Kim; Da-Hyun Koo; Jeong-Mo Choi
Journal:  BMB Rep       Date:  2022-08       Impact factor: 5.041

Review 9.  Dysregulation of Translation in TDP-43 Proteinopathies: Deficits in the RNA Supply Chain and Local Protein Production.

Authors:  Reed T Bjork; Nicholas P Mortimore; Suvithanandhini Loganathan; Daniela C Zarnescu
Journal:  Front Neurosci       Date:  2022-03-07       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.